PagesStructures['id1480980038682'] = {"structures":[{"type":"page","id":"id1480980038682","elementProperties":{"tagName":"DIV","behaviours":null,"isLocked":false,"name":"Oncology","baseName":"Events","templateID":null,"templateName":null,"order":0,"customStates":null,"isElementWasEditedInMode":true,"showHoverEffects":true,"skinInformation":{},"isSupportsMobile":false,"isVisibleInMode":true,"isFixed":false,"topZIndex":0,"elementOpacity":1,"staticMargin":{"horizontalMargin":0,"verticalMargin":0},"sizeAndPosition":{"width":0,"height":1068,"top":0,"left":0},"lastResizingSize":{"width":0,"height":1068,"top":0,"left":0},"isVisibleInLastSection":true,"isVisibleInLastDataItem":true,"attributes":null,"metaProps":null,"metaItemType":null,"metaTitle":null,"styleBindingId":null,"styleBindingFields":null,"shadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"glow":{"spread":0,"blur":0,"color":"black"},"isParallaxBackground":false,"parallaxBackgroundSpeed":0.5,"isParallaxElement":{"isActive":false,"speed":1,"delay":0},"effectsOptions":{"isParallax":false,"oneTimeAnimation":false,"duration":1200,"startDistance":200,"startVisibility":0.8,"distance":300,"measureDistanceType":3,"delay":0,"distanceDelay":0,"runInLoop":false,"flyDirection":2,"direction":"horizontal","movementDistanceHorizontally":200,"movementDistanceVertically":0,"autoStartDistanceSettings":true,"autoDistanceSettings":true},"effects":null,"binding":null,"verticalAlign":"center","horizontalAlign":"center","horizontalContentAlign":"center","basicUserCanEdit":true,"overflow":false,"isGrowable":{"bottom":false,"right":false},"rowsItems":null,"childrenAnchor":"center","backgroundColor":{"mainColor":0,"variation":0,"opacity":1,"brightness":0},"imageUrl":{"id":64223,"imagePath":"bmKeh-Td3UKEnUqpixpZSg.jpg","thumbPath":"bmKeh-Td3UKEnUqpixpZSg_thumb.jpg","ownerID":500004,"storageServer":6,"scaledVersions":[{"size":200,"suffix":"_200"},{"size":400,"suffix":"_400"},{"size":600,"suffix":"_600"},{"size":800,"suffix":"_800"},{"size":1000,"suffix":"_1000"},{"size":1450,"suffix":"_1450"}],"imageWidth":2200,"imageHeight":1650},"imageLayout":"stretchedToFill","imagePosition":{"horizontal":"center","vertical":"top"},"origImage":"","imageOpacity":0.1,"backgroundOverlay":"transparent","gridLines":[],"fixedBackground":false,"statesGroups":null},"metaData":{"position":{"left":-721.5,"top":0},"size":{"width":1443,"height":10496}},"childElements":[{"type":"SectionElement","id":"id1480980137600","elementProperties":{"tagName":"SECTION","behaviours":null,"isLocked":false,"name":"Section 5","baseName":null,"templateID":null,"templateName":null,"order":3,"customStates":null,"isElementWasEditedInMode":false,"showHoverEffects":true,"skinInformation":{},"isSupportsMobile":false,"isVisibleInMode":true,"isFixed":false,"topZIndex":0,"elementOpacity":1,"staticMargin":{"horizontalMargin":0,"verticalMargin":0},"sizeAndPosition":{"height":10126,"left":0,"width":1082,"top":0},"lastResizingSize":{"height":9874,"left":0,"width":1082,"top":0},"isVisibleInLastSection":true,"isVisibleInLastDataItem":true,"attributes":null,"metaProps":null,"metaItemType":null,"metaTitle":null,"styleBindingId":null,"styleBindingFields":null,"shadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"glow":{"spread":0,"blur":0,"color":"black"},"isParallaxBackground":false,"parallaxBackgroundSpeed":0.5,"isParallaxElement":{"isActive":false,"speed":1,"delay":0},"effectsOptions":{"isParallax":false,"oneTimeAnimation":false,"duration":1200,"startDistance":200,"startVisibility":0.8,"distance":300,"measureDistanceType":3,"delay":0,"distanceDelay":0,"runInLoop":false,"flyDirection":2,"direction":"horizontal","movementDistanceHorizontally":200,"movementDistanceVertically":0,"autoStartDistanceSettings":true,"autoDistanceSettings":true},"effects":null,"binding":null,"innerGlow":{"spread":0,"blur":0,"color":"black"},"innerShadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"padding":{"top":0,"left":0,"bottom":0,"right":0},"basicUserCanEdit":true,"backgroundColor":"transparent","imageUrl":"","imageLayout":"stretchedToFill","imagePosition":{"vertical":"center","horizontal":"center"},"origImage":"","imageOpacity":1,"backgroundOverlay":"transparent","verticalLayout":"normal","horizontalLayout":"normal","fillLayout":{"fillVertical":false,"fillHorizontal":false},"margin":{"top":0,"left":0,"bottom":0,"right":0},"overflow":false,"isGrowable":{"bottom":false,"right":false},"rowsItems":null,"childrenAnchor":"center","resizingGripPosiotion":"s","sectionName":"Section A","pageContentType":1,"borderWidth":{"top":0,"left":0,"bottom":0,"right":0},"roundness":{"topLeft":0,"bottomLeft":0,"topRight":0,"bottomRight":0},"borderColor":{"top":"Black","left":"Black","bottom":"Black","right":"Black"},"borderStyle":{"top":"solid","left":"solid","bottom":"solid","right":"solid"}},"metaData":{"position":{"left":-721.5,"top":251},"size":{"width":1443,"height":10126}},"childElements":[{"type":"freeText","id":"id1481497224128","elementProperties":{"tagName":"DIV","behaviours":null,"isLocked":false,"name":"Text 7","baseName":null,"templateID":"templateid1481497224129","templateName":null,"order":46,"customStates":null,"isElementWasEditedInMode":false,"showHoverEffects":true,"skinInformation":{},"isSupportsMobile":false,"isVisibleInMode":true,"isFixed":false,"topZIndex":0,"elementOpacity":1,"staticMargin":{"horizontalMargin":0,"verticalMargin":0},"sizeAndPosition":{"width":858,"height":9946,"left":-437,"top":106},"lastResizingSize":{"width":858,"height":9694,"left":-437,"top":106},"isVisibleInLastSection":true,"isVisibleInLastDataItem":true,"attributes":null,"metaProps":null,"metaItemType":null,"metaTitle":null,"styleBindingId":null,"styleBindingFields":null,"shadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"glow":{"spread":0,"blur":0,"color":"black"},"isParallaxBackground":false,"parallaxBackgroundSpeed":0.5,"isParallaxElement":{"isActive":false,"speed":1,"delay":0},"effectsOptions":{"isParallax":false,"oneTimeAnimation":false,"duration":1200,"startDistance":200,"startVisibility":0.8,"distance":300,"measureDistanceType":3,"delay":0,"distanceDelay":0,"runInLoop":false,"flyDirection":2,"direction":"horizontal","movementDistanceHorizontally":200,"movementDistanceVertically":0,"autoStartDistanceSettings":true,"autoDistanceSettings":true},"effects":null,"binding":null,"innerGlow":{"spread":0,"blur":0,"color":"black"},"innerShadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"display":"fixed","cellItem":null,"cellHorizontalAlignment":"none","basicUserCanEdit":true,"backgroundColor":"transparent","imageUrl":"","imageLayout":"stretchedToFill","imagePosition":{"vertical":"center","horizontal":"center"},"origImage":"","imageOpacity":1,"backgroundOverlay":"transparent","isVisible":true,"verticalLayout":"normal","horizontalLayout":"normal","fillLayout":{"fillHorizontal":false,"fillVertical":false},"margin":{"top":0,"left":0,"bottom":0,"right":0},"borderWidth":{"top":0,"left":0,"bottom":0,"right":0},"roundness":{"topLeft":0,"bottomLeft":0,"topRight":0,"bottomRight":0},"borderColor":{"top":"Black","left":"Black","bottom":"Black","right":"Black"},"borderStyle":{"top":"solid","left":"solid","bottom":"solid","right":"solid"},"padding":{"top":0,"left":0,"bottom":0,"right":0},"rotationAngle":0,"verticalAlign":"center","horizontalAlign":"left","horizontalContentAlign":"center","startSelected":false,"urlAddress":null,"openInNewTab":false,"openInTopWindow":false,"shouldUnderlineChildren":false,"namedTextStyle":null,"fontColor":{"mainColor":2,"opacity":1,"brightness":0},"textShadow":[],"lineHeight":{"pixels":14,"percentages":120,"unit":"percentages"},"letterSpacing":0,"fontSize":14,"font":{"themeFont":"body1"},"contentTextTransform":"none","isBold":false,"isItalic":false,"isUnderline":false,"textStyle":{"bold":false,"underline":false,"italic":false},"textDirection":2,"dataBinding":null,"formattedText":"

General

Published by Mass General Brigham [FR, writer]:
National Analysis: Suicide Is an Important Risk After Cancer Surgery, 11-13-2023.
COVID-19 vaccination is protective, well tolerated in cancer patients, 6-12-2023.
Novel technology finds new targets among so-called 'undruggable' cancer targets, 4-24-2023.
Intervening to reduce cancer caregiver stress, 3-21-2023.
Enhanced interferon signaling may improve CAR T-cell immunotherapy for solid tumors, 11-9-2022.
Weber J, Dolan D, Vafadar S. Maximizing the clinical benefit of immune checkpoint inhibitors: fostering an environment of collaborative care and communication. Online CME program. Prepared November 2015. [BAC and FR, collaborating writers]
Caley BA. Added benefits: what healthcare reform means for people with cancer. CURE: Cancer Updates, Research and Education. Published online December 10, 2013.
Caley BA. Non-traditional methods to pay for cancer care pays off. CURE: Cancer Updates, Research and Education. Published online November 25, 2013.
\"Oncology\" (board review slide set). American Geriatrics Society. Updated 2013. [BAC and FR, writers]
Recent developments in cancer (biologic and targeted therapies, gene therapy, therapeutic vaccines, and individualized treatment). Educational website content for patients and the public. Prepared January to June 2007. [BAC, writer]
Caley BA. The future of cancer research: recent discoveries will change the direction of treatment. CURE: Cancer Updates, Research and Education. 2005;4(4):48-55.
Quantitative literature analyses about: a hematopoietic growth factor (prepared April 2005), a novel leukemia drug (March 2005), a novel taxane (February 2005), monoclonal antibodies for breast cancer (February 2005), a novel anthracenedione (February 2005), and various antimicrobials (January 2005). [BAC, researcher]
Walsh JME. Controversies in cancer prevention and screening. Adv Stud Med. 2003;3(6):316-325. [BAC and FR, collaborating writers]

Adverse event management -- see Supportive care

Bladder cancer

Published by Mass General Brigham [FR, writer]:

Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates, 2-12-2024.

Urine Test Validated for Diagnosis, Surveillance and Risk Prediction in Urothelial Carcinoma, 11-27-2023.

Checkpoint inhibitors and other immunotherapies in urologic cancer, 5-9-2023.

High MRE11 in muscle-invasive bladder tumors linked to better survival after chemoradiation, 1-5-2023.

Long-term safety profile of salvage cystectomy after trimodality therapy seems acceptable, 6-22-2021.

Considerations in selecting patients for trimodality therapy for muscle-invasive bladder cancer, 6-21-2021.
Updates in staging and reporting of genitourinary malignancies, 11-30-2020.

Atezolizumab as adjuvant therapy for BK polyomavirus–associated urothelial cancer, 9-27-2020.

Immune and stromal infiltration in invasive bladder cancer predict response to therapy, 11-12-2019.

Gene profiling of bladder tumors shows promise for identifying candidates for trimodality therapy, 8-15-2019.

Low-risk incidental prostate cancer in men with bladder cancer may be associated with longer survival, 8-15-2019.

Improving cost-effectiveness of second-line pembrolizumab for advanced urothelial carcinoma, 2-18-2019.

Alternative chemoradiation regimen of trimodal therapy found effective for muscle-invasive bladder cancer, 1-29-2019.

Trimodality therapy provides better quality of life than radical cystectomy in muscle-invasive bladder cancer, 1-15-2019.

Zibelman M. Highlights from ASCO GU: Locally advanced or metastatic urothelial carcinoma. Online CME presentation. Prepared March 2021. [BAC, collaborating writer]
Crispen P, Kusmartsev S. Bladder cancer immunotherapy. University of Florida newsletter. Prepared April 2020. [BAC, collaborating writer]
Petrylak DP. \"Immunotherapy: The Wave of the Future in Bladder Cancer.\" Supplement to J Clin Genitourin Cancer. Prepared February 2017. [FR, collaborating writer]
Caley BA. Bladder cancer: breaking the research barrier. CURE: Cancer Updates, Research and Education. 2006;5(5):34-39,44-45.

Brain metastases

Published by Mass General Brigham [FR, writer]:

Palbociclib demonstrates activity against progressive brain metastases harboring CDK pathway alterations, 6-23-2022.
Combination checkpoint inhibitor therapy safe, extends survival for leptomeningeal disease, 6-23-2022.
Cell-free DNA analysis outperforms cytology for diagnosing leptomeningeal disease, 6-23-2022.

Breast cancer

Published by Mass General Brigham [FR, writer]:

Deep learning model outperforms traditional models for predicting breast cancer in women at high risk, 1-22-24.

Case report: Genomic testing identifies NTRK fusions in patient with refractory metastatic breast cancer, 7-2-2023.

Novel intraoperative fluorescence guidance identifies residual tumor during lumpectomy, 6-23-2023.

Cell-free DNA assay can identify microsatellite instability–high status in advanced breast cancer, 1-4-2023.

Time for change in digital breast tomosynthesis research, 6-9-2022.

Emerging indications for contrast-enhanced mammography, 3-29-2022.

Novel mechanism of resistance to sacituzumab govitecan in triple-negative breast cancer identified, 3-9-2022.

Magnetic particle imaging may allow intraoperative breast tumor margin assessment, 10-26-2021.

Pragmatic approach to managing and interpreting breast imaging after COVID-19 vaccination, 5-10-2021.

Digital breast tomosynthesis superior to mammography for surveillance of breast cancer survivors, 3-15-2021.

Sacituzumab govitecan-hziy effective for heavily pretreated metastatic triple-negative breast cancer, 3-8-2020.

New insight into breast cancer metastasis—and the potential for preventing it, 12-2-2020.

Knippa E. Abbreviated protocols for breast cancer screening: do they work? Online CME program. Prepared June 2018. [BAC, collaborating writer]
Sequencing therapy in HER2-positive breast cancer: a conversation with Sara Hurvitz, MD. Online CME program. Prepared April 2015. [BAC, collaborating writer]
DeMartini W. Application of MRI for treatment decisions in breast cancer. Online CME program. Prepared September 2014. [BAC, collaborating writer]
The use of nontaxane microtubule dynamics inhibitors to treat metastatic breast cancer. Needs assessment for a CME program for oncologists. Prepared May 2013. [BC, writer]
Modi S. First-line treatment for newly diagnosed HER2-positive metastatic breast cancer. Online CME program. Prepared March 2013. [FR, collaborating writer]
Hurvitz S. Recurrent, previously treated HER2-positive metastatic breast cancer. Online CME program. Prepared February 2013. [BAC, collaborating writer]
Inflammatory local recurrence after breast-conserving therapy for breast cancer. Journal article prepared September 2012. [FR, collaborating editor]
Management of pretreated metastatic breast cancer. Needs assessment for a CME program for oncologists. Prepared May 2010. [BAC and FR, writers]
Current third-line treatment of breast cancer. Benchmarking report prepared July 2009. [BAC, writer]
Slide sets on breast cancer-related abstracts and posters presented at ASCO 2009. Prepared June 2009. [BAC, writer]
Anti-angiogenic therapy in breast, colorectal, ovarian, and renal cancer. Monograph prepared June to September 2008. [FR, writer]
Three posters for ASCO annual meeting about anti-angiogenic treatment of breast and ovarian cancer. Prepared April 2008. [FR, collaborating writer]
Same-day Internet reports from the San Antonio Breast Cancer Symposium. Prepared for CURE magazine, December 2008. [BAC, writer]
Caley BA. In situ breast cancer: is it really cancer? CURE: Cancer Updates, Research and Education. 2006;5(4):18-23,28. Also wrote sidebar: Do women under 50 need mammograms?
Preventing death from breast cancer and prostate cancer. Taking Care. November 2005. [BAC, writer]
Meeting report, national breast cancer advisory board. Prepared June 2005. [FR, writer]
Meeting report, national breast cancer advisory board. Prepared June 2004. [BAC, writer]
Caley BA and Reidenbach F. Expanding options for advanced breast cancer. CURE: Cancer Updates, Research and Education. 2003;2(3):47-53.
Reidenbach F. Gabapentin may relieve tamoxifen-related hot flushes. Lancet Oncol. 2002;3:393.
Published by Reuters news for physicians [FR, writer]:

Novel predictor of breast cancer survival called the most powerful to date, 11-14-2002.

Anthracycline/taxane neoadjuvant chemotherapy advised for breast cancer, 4-9-2002.

Clues to why breast cancer more often fatal in African Americans, 2-7-2002.

Postmastectomy radiation may be warranted after response to chemotherapy, 1-30-2002.

Carcinoid tumor

Report on current standards of care for prostate, pancreatic, and head and neck cancer, and carcinoid tumor. Prepared November 2005. [FR, writer]

Cervical cancer

Published by Mass General Brigham [FR, writer]:

Specialty palliative care underutilized for patients with cervical cancer, 1-20-2021.

Minimally invasive surgery linked to shorter survival in early-stage cervical cancer, 11-30-2018.

CME newsletter about the burden of cervical cancer. Prepared September 2006. [FR, writer]
Reidenbach F. Public funding of Pap tests linked to lower rate of invasive cervical cancer. Reuters news for physicians, 7-5-2002.

Colorectal cancer

Published by Mass General Brigham [FR, writer]:

Post-diagnosis Multivitamin Supplementation May Prolong Survival Among Patients with Nonmetastatic CRC, 4-15-2024.

Vitamin C Might Have Clinical Benefit Against KRAS- and BRAF-Mutated CRC, 2-19-2024.

Adagrasib With or Without Cetuximab Shows Activity Against CRC With Mutated KRAS G12C, 1-1-2024.

Likelihood of Death at Home Is Improving in Colorectal Cancer, but Sociodemographic Disparities Persist, 12-4-2023.

Preoperative Alzheimer's Disease and Related Dementias Influence Outcomes of Colorectal Surgery, 10-23-2023.

Mortality risk significantly greater with interval CRC than screen-detected CRC, 11-10-2022.

Initiating screening before age 50 reduces risk of colorectal cancer, 7-8-2022.

Sulfur microbial diet linked to precursor of early-onset colorectal cancer, 2-15-2022.

Size of largest colorectal liver metastasis is an independent prognostic factor after neoadjuvant therapy, 5-21-2021.

Anatomic classification of colorectal cancer is too broad for accurate risk prediction, 9-18-2020.

Sulfur-metabolizing bacteria linked to increased risk of colorectal cancer, 4-14-2020.

Primary tumor resection improves survival in advanced colorectal cancer, 11-6-2019.

Intensive surveillance may not be needed for non-advanced colorectal adenomas, small serrated polyps, 10-15-2019.

TV viewing time may affect risk of young-onset colorectal cancer, 3-15-2019.

Fiber intake has survival benefit in patients already diagnosed with colorectal cancer, 2-18-2019.

Antibiotic use linked to colorectal adenoma in women, 1-21-2019.

Report on novel neoadjuvant therapy for rectal cancer. University of Florida newsletter. Prepared February 2020. [BAC, writer]
2 executive summaries of advisory boards about dual-targeted therapy for colorectal cancer. Prepared April and June 2019. [FR, writer]
Bekaii-Saab TS, Rone K. The nurse view: managing adverse events in progressive metastatic colorectal cancer. Online CME program. Prepared May 2018. [FR, collaborating writer]
Grothey A. Management of mCRC upon disease progression: a challenge in practice. Case-based online CME program. Prepared April 2016. [FR, collaborating writer]
Chu E. Clinical challenges in metastatic colorectal cancer: beyond the first line. Online CME program. Prepared July 2014. [BAC, collaborating writer]
McIntyre KR. New targeted agents in metastatic colorectal cancer: a guide for oncology nurses. Online continuing education program. Prepared December 2013. [BAC, collaborating writer]
Script for sales training video on KRAS as a biomarker for response to treatment of colorectal cancer. Prepared October 2009. [BAC, writer]
Detailed summaries of published journal articles about anti-angiogenic therapy in breast, colorectal, ovarian, and renal cancer. Prepared June to September 2008. [FR, writer]
Educational website content for patients with colorectal cancer. Prepared January to June 2007. [BAC, writer]
Poster for ASCO annual meeting about outcome measures for clinical trials of agents for metastatic colorectal cancer. Prepared April 2006. [FR, collaborating writer]
Review article about the use of an anti-angiogenesis agent in the treatment of metastatic renal cell carcinoma. Prepared January 2006. [FR, collaborating writer]
Reidenbach F. Gene may help suppress colorectal cancer. Reuters news for the public, 2-28-2002.

Endometrial cancer

Published by Mass General Brigham [FR, writer]:

Prophylactic surgery for women at risk of hereditary ovarian or endometrial cancer, 9-18-2019.
Minimally invasive hysterectomy improves outcomes in women with early endometrial cancer, 4-8-2019.

Glioma

Published by Mass General Brigham [FR, writer]:

Oncolytic Herpes Simplex Viruses for Treatment of Glioma, 12-25-2023.
Putative Therapeutic Targets for Rare Astrocytoma May Also Apply to IDH1-Mutant Glioma, 12-18-2023.
Tumor Treating Fields Reconceptualized As a Targeted, Invasive Therapy for Glioma, 9-18-2023.
Novel tandem CAR T-cell therapy effective against heterogeneous glioblastoma, 4-3-2023.
Targeting lipid synthesis efficacious in glioblastoma mouse models, 2-28-2023.
Implications of IDH mutations for success of glioma immunotherapy, 5-17-2022.
Local NAMPT inhibition enhances checkpoint immunotherapy for glioblastoma, 1-21-2021.
Circulating blood counts predict response, survival in recurrent glioblastoma treated with bevacizumab, 8-18-2020.
Novel combination therapy highly effective against IDH-mutant glioma, 8-5-2020.
Gene fusions detected in plasma of glioblastoma patients, suggesting new approach to liquid biopsy, 6-18-2020.
New cellular “blueprint” of glioblastoma explains why it’s so hard to treat, 4-27-2020.
Liquid biopsy using fluorescent extracellular vesicles shows promise for diagnosis of glioma, 3-5-2020.
New approach to CAR T-cell therapy for glioblastoma aims to circumvent antigen escape, 8-23-2019.
New tool measures glioma response to treatment automatically, 8-9-2019.
Noninvasive measurement of brain activity might improve prognostication, treatment of glioma, 4-17-2019.
Surgery may not improve survival after first documented progression of glioblastoma, 1-15-2019.
New subtype of glioblastoma identified, 11-26-2018.
New targeted glioma therapy could suppress tumor growth: interview with Daniel P. Cahill, MD, PhD, 8-9-2018.

Head and neck cancer

BRD4 inhibitors may be effective against a subset of head and neck squamous cell carcinomas. Published by Mass General Brigham, 12-15-2022. [FR, writer]
Slide deck about using a farnesyltransferase inhibitor for head and neck cancer. Prepared March 2020. [FR, writer]
Review article about the use of immunotherapy in head and neck cancer. Prepared November 2008. [BAC and FR, collaborating writers]
Report on current standards of care for prostate, pancreatic, and head and neck cancer, and carcinoid tumor. Prepared November 2005. [FR, writer]

Liver/bile duct cancer

Published by Mass General Brigham [FR, writer]:
Futibatinib efficacious for FGFR2 fusion/rearrangement–positive intrahepatic cholangiocarcinoma in phase 2 multinational trial, 6-27-2023.
Novel AI model predicts risk of hepatic toxicity after radiation therapy for HCC, 6-16-2023.
Resection is best option for hepatocellular carcinoma patients with Child–Pugh A cirrhosis, 8-15-2019.
Challenges in unresectable hepatocellular carcinoma: what would you do? Case-based online CME program. Prepared March 2016. [FR, collaborating writer]

Lung cancer

Published by Mass General Brigham [FR, writer]:
Molecular Features Identified That Predict Response to Checkpoint Inhibitors in NSCLC, 1-22-2024.
Factors identified that influence lymph node harvest during esophagectomy by thoracic surgeons, 7-21-2023.
Lymph node harvest, upstaging after lobectomy for NSCLC linked to hospital volume, 7-19-2023.
Pulmonary function at time of lung cancer diagnosis has prognostic value, 7-11-2023.
Paclitaxel-loaded mesh reduces local recurrence of lung cancer in animal model, 5-22-2023.
New AI tool predicts six-year lung cancer risk from a single CT scan, 4-13-2023.
Managing lung cancer in patients with interstitial lung disease, 2-16-2023.
Robotic approach to lobectomy safe and feasible for stage II–IIIa NSCLC, 12-21-2022.
Overcoming barriers to lung cancer screening, 12-12-2022.
Radiology is underrepresented on websites of lung cancer screening programs, 12-2-2022.
First-in-human trial: Implanted microdevice for testing patient sensitivity to multiple chemotherapeutic agents in NSCLC, 9-15-2022.
Olaparib/temozolomide promising for relapsed small-cell lung cancer, 9-13-2021.
Capmatinib benefits adults with advanced NSCLC and MET exon 14 skipping mutation, 3-17-2021.
EGFR-FGFR blockade might overcome drug resistance in EGFR-mutant non-small-cell lung cancer, 11-12-2019.
Ramalingam S, Garon EB, Govindan R, Mok T, Rizvi N, Scagliotti G. Updates in lung cancer: insights from Vienna. Online CME program. Prepared December 2016. [BAC, collaborating writer]
Wakelee HA, Goldberg SB, Stinchcombe TE. Reflecting on errors and missed opportunities in non-small cell lung cancer. Online CME program. Prepared June 2016. [FR, collaborating writer]
Socinski MA, Yung RC, Wistuba I, Clark AL. A multidisciplinary approach in advanced NSCLC in the era of immuno-oncology. Online CME program. Prepared January 2016. [FR, collaborating writer]
Training materials for sales representatives about targeted therapy for non-small-cell lung cancer. Prepared June 2008, February 2009, and September 2009. [FR, writer]
Qualitative literature review on video-assisted thoroscopic lobectomy. Prepared May 2007. [FR, researcher]
Educational website content for patients with non-small-cell or small-cell lung cancer. Prepared January to June 2007. [BAC, writer]
The health consequences of smoking. In: Attorneys’ Textbook of Medicine. New York, NY: Matthew Bender, 2006. [BAC, collaborating writer]
Review article about trends in chemotherapy for lung cancer. Prepared July 2005. [FR, collaborating writer]
Quantitative literature analysis regarding chemotherapy for non-small-cell lung cancer. Prepared April 2004. [BAC, researcher]
Reidenbach F. Early radiation advised for limited-stage small-cell lung cancer. Reuters news for physicians, 8-7-2002.
Reidenbach F. Spiral CT promising for lung cancer screening. Reuters news for the public, 8-2-2002.
Reidenbach F. p53 appears to inhibit angiogenesis in non-small-cell lung cancer. Reuters news for physicians, 3-13-2002.

Neuroendocrine tumors

Section 3 (review of clinical evidence) of an AMCP dossier for a drug used in the treatment of gastropancreatic neuroendocrine tumors. Prepared December 2014. [FR, writer]
Phan A, Kulke MH, Yao JC, Strosberg JS, Kunz PL. The evolving treatment landscape of pancreatic neuroendocrine tumors. Online CME presentation. Prepared April 2013. [BC, collaborating writer]
Saif MW, Scheiman JM. Standard of care for pancreatic endocrine tumors. Online CME program. Prepared April 2011. [BAC, collaborating writer]

Ovarian cancer

Published by Mass General Brigham [FR, writer]:

Comprehensive Lymphadenectomy Often Unnecessary for Primary Endometrioid Ovarian Carcinoma, 2-12-2024.

Prophylactic surgery for patients at high risk of ovarian cancer decreases sexual function, quality of life, 5-24-2022.

Prophylactic surgery for women at risk of hereditary ovarian or endometrial cancer, 9-28-2019.

Risk of death after cytoreduction of advanced ovarian cancer differs by age, 7-12-2019.

Report on newest robotic surgery techniques for ovarian cancer. University of Florida newsletter. Prepared February 2020. [BAC, writer]
Detailed summaries of published journal articles about anti-angiogenic therapy in breast, colorectal, ovarian, and renal cancer. Prepared June to September 2008. [FR, writer]
Three posters for ASCO annual meeting about anti-angiogenic treatment of breast and ovarian cancer. Prepared April 2008. [FR, collaborating writer]

Pancreatic cancer

Published by Mass General Brigham [FR, writer]:

Neoadjuvant Therapy Appears Safe, Effective for Elderly Patients With Pancreatic Ductal Adenocarcinoma, 11-20-2023.

An epigenetic approach to treating pancreatic cancer, 4-12-2023.
Management of pancreatic acinar cell carcinoma, 8-2-2021.

Stromal microenvironment shapes the \"architecture\" of pancreatic tumors, affecting survival and treatment response, 10-16-2020.

Staging laparoscopy leads to longer life in patients with resectable pancreatic cancer, 1-29-2019.

Report on consortium to find biomarkers for pancreatic cancer. University of Florida newsletter. Prepared March 2020. [BAC, writer]
Staging laparoscopy leads to longer life in patients with resectable pancreatic cancer. Massachusetts General Hospital Advances in Motion, 1-29-2019. [FR, writer]
Morton A, Jacobs CB, Valone T. The nurse view: management of pancreatic adenocarcinoma. Online continuing education program. Prepared October 2014. [FR, collaborating writer]
Training materials for sales representatives about targeted therapy for pancreatic cancer. Prepared June 2008, February 2009, and September 2009. [FR, writer]
Report on current standards of care for prostate, pancreatic, and head and neck cancer, and carcinoid tumor. Prepared November 2005. [FR, writer]
Reidenbach F. Statins might fight spread of pancreatic cancer. Reuters news for the public, 3-29-2002.

Pituitary cancer

Menopausal hormone therapy linked to increased risk of pituitary cancer. Published by Mass General Brigham, 6-21-2022. [FR, writer]

Prostate cancer

Published by Mass General Brigham [FR, writer]:
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer, 5-27-2024.
Triple Therapy Prolongs Survival in High-volume and High-risk/Low-risk Metastatic Hormone-Sensitive Prostate Cancer, 4-15-2024.
Auto-contouring model performs well for prostate cancer patients who receive radiopaque hydrogel spacer, 5-16-2023.
Checkpoint inhibitors and other immunotherapies in urologic cancer, 5-9-2023.
Combined standard and targeted transperineal biopsies advised for patients with prostate lesion on multiparametric MRI, 5-1-2023.
Primary prostate cancer establishes a suppressive immune microenvironment, 3-17-2023.
Metabolomic information highly useful for predicting future prostate cancer, 2-16-2023.
Case series: mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma, 1-30-2023.
Combination of darolutamide, ADT and docetaxel improves survival of patients with metastatic, hormone-sensitive prostate cancer, 1-20-2023.
Targeted biopsy alone detects clinically significant cancer in smaller prostates, 12-13-2022.
Active surveillance for intermediate-risk prostate cancer, 10-12-2022.
  New tool assists in the evaluation of abdominal pain after robotic-assisted laparoscopic prostatectomy, 6-7-2022.
Role of DNA damage response genes in prostate cancer similar for African Americans, European Americans, 3-31-2022.
Predicted survival after radical prostatectomy varied by race with a trained machine classifier, 3-4-2022.
Cardiac risk substantially lower with enzalutamide than abiraterone, 1-7-2022.
Combination prostate biopsy can overestimate Gleason grade compared with surgical pathology, 1-4-2022.
MRI–ultrasound fusion–targeted transperineal prostate biopsy complements standard biopsy for detecting perineural invasion, 12-14-2021.
Transperineal prostate biopsy feasible in outpatient practice, 11-5-2021.
MRI promising for prostate cancer screening in the asymptomatic general population, 4-1-2021.
Darolutamide delays metastasis and death in patients with nonmetastatic, castration-resistant prostate cancer, 3-20-2021.
Prostate cancer patients with positive posterior surgical margins have poorer prognosis, 3-15-2021.
Updates in staging and reporting of genitourinary malignancies, 11-30-2020.
Risk of prostate cancer recurrence correlates with number of perineural invasion foci, 9-14-2020.
Genetic tests improve prognostication for newly diagnosed patients with prostate cancer, 5-4-2020.
Active surveillance of prostate cancer is a viable option for men under 60, 2-27-2020.
Low-risk incidental prostate cancer in men with bladder cancer may be associated with longer survival, 8-15-2019.
Multifocality and multilocation of positive margins predict biochemical recurrence of prostate cancer, 11-13-2018.
Stringer T. Fusion of MRI and ultrasound for prostate biopsy. University of Florida newsletter. Prepared February 2020. [BAC, collaborating writer]
Sartor O. Understanding the mechanism of radionuclides and survival in bone mets in castrate-resistant prostate cancer. Online CME program. Prepared April 2018. [FR, collaborating writer]
Ryan CJ. Treating bone metastases in castration-resistant prostate cancer. Case-based online CME program. Prepared May 2015. [BAC, collaborating writer]
Needs assessment for a CME program for oncologists about metastatic castration-resistant prostate cancer. Prepared October 2012. [BAC and FR, writers][
Protection against bone loss in patients with nonmetastatic prostate cancer treated with androgen deprivation therapy. Review article for urology nurses. Prepared September 2009. [FR, collaborating writer]
Review article about the safety of testosterone replacement therapy with regard to prostate cancer. Prepared April 2006. [BAC and FR, collaborating writers]
Report on current standards of care for prostate, pancreatic, and head and neck cancer, and carcinoid tumor. Prepared November 2005. [FR, writer]
Preventing death from breast cancer and prostate cancer. Taking Care. November 2005. [BAC, writer]
Reidenbach F. Telomerase immunoreactivity of prostate tumors may have diagnostic value. Reuters news for physicians, 12-27-2002.

Rectal cancer

PET/MRI superior to MRI alone for staging of rectal cancer. Published by Mass General Brigham, 2-26-2021. [FR, writer]

Renal cell carcinoma

Published by Mass General Brigham [FR, writer]:

Genetic signature predicts metastasis, survival in clear cell renal cell carcinoma, 1-19-2023.
Biopsy tract seeding resulting in perirenal tissue involvement in RCC may not warrant upstaging, 7-27-2021.

Updates in staging and reporting of genitourinary malignancies, 11-30-2020.

Laterality of renal cell carcinoma predicts survival in certain patient subgroups, 10-15-2019.

Microwave ablation: another nephron-sparing option for localized RCC, 11-7-2019.

Zibelman M. Highlights from ASCO GU: Renal cell carcinoma. Online CME presentation. Prepared March 2021. [BAC, collaborating writer]
Terry R. Development of artificial intelligence algorithm to assess kidney tumors. University of Florida newsletter. Prepared February 2020. [BAC, collaborating writer]
McDermott DF. Patient-centered care in metastatic renal cell carcinoma. Case-based CME program. Prepared September 2016. [BAC, collaborating writer]
Motzer R. Tyrosine kinase inhibitor therapy for advanced renal cell carcinoma: current and emerging agents. Online CME program. Prepared November 2011. [FR, collaborating writer]
Kim J. Management approaches for metastatic renal cell carcinoma. Online CME program. Prepared March 2011. [BAC, collaborating writer]
Detailed summaries of published journal articles about anti-angiogenic therapy in breast, colorectal, ovarian, and renal cancer. Prepared June to September 2008. [FR, writer]
Caley BA. Picking up momentum for treating renal cell carcinoma. CURE: Cancer Updates, Research and Education. 2006;5(1):34-42.
Reidenbach F. Capecitabine promising for advanced renal cell carcinoma. Reuters news for physicians, 1-23-2002.

Sarcoma

Published by Mass General Brigham [FR, writer]:
Metastatic patterns vary substantially between subtypes of soft tissue sarcoma, 7-17-2023.
Radiation therapy benefits patients with locally resectable extraskeletal osteosarcoma, 1-20-2020.
Targeting CD44 with CRISPR gene editing may improve prognosis of osteosarcoma, 3-15-2019.
Iqbal S. Essential concepts in the management of gastrointestinal stromal tumor. Case-based CME program. Prepared May 2016. [FR, collaborating writer]
Caley BA. The new sarcoma story: strategies for diagnosing and treating sarcomas shift to a more patient-specific approach. CURE: Cancer Updates, Research and Education. 2007;6(5):42-49.
Caley BA. Singling out sarcoma: why everyone should care about this uncommon disease. CURE: Cancer Updates, Research and Education. 2004;3(2):56-60, 62-63.

Skin cancer

Published by Mass General Brigham [FR, writer]:

Considering both tumor and immune features may improve prediction of melanoma outcomes after checkpoint inhibition, 12-15-2022.

Activating CD4+ T cells at benign nevi might prevent melanoma, 9-19-2022.

39 biopsies, nine years: mapping evolution of resistance to melanoma immunotherapy in a former complete responder, 4-26-2022.

Executive summary of an advisory board about dual-targeted therapy for melanoma. Prepared March 2019. [FR, writer]
Perez MC, Zager JS, Amatruda T, et al. Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). Melanoma Management. 2019;6(2):MMT19. [BAC and FR, collaborating writers]
Gibney GT. Incorporating patient-centered management in metastatic melanoma. Online CME program. Prepared September 2015. [FR, collaborating writer]
Diagnosis and treatment of basal cell carcinoma. Needs assessment for a CME program for dermatologists and dermatologic oncologists. Prepared August 2012. [BAC and FR, writers]

Supportive care

Smartphone app improves adherence to oral cancer chemotherapy by certain patients. Published by Mass General Brigham, 4-27-2020. [FR, writer]
Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Education. 2020; 35(1): 178–186. [FR, collaborating writer]
Raskob G. What every oncologist should know about thromboembolic risk. Online CME program. Prepared April 2018. [BAC, collaborating writer]
Section 3 (review of clinical evidence) of an AMCP dossier about biosimilar filgrastim. Prepared June 2015. [FR, writer]
Ryan CJ. Treating bone metastases in castration-resistant prostate cancer. Case-based online CME program. Prepared May 2015. [BAC, collaborating writer]
Howard SC, Harvey RD, Kovacsovics T, Wood N. Life-threatening chemotoxicity: from prevention to management. Online CME program. Prepared April 2014. [FR, collaborating writer]
Cairo MS. Tumor lysis syndrome: understanding, preventing, and managing an oncologic emergency. Online CME program. Prepared April 2012. [BAC, collaborating writer]
Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T. Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 2012;81(2):136-150. [BAC and FR, collaborating writers]
The use of denosumab to prevent cancer treatment-induced bone loss. CME monograph prepared June 2010. [FR, collaborating writer]
Needs assessment for CME program on preventing venous thromboembolism in cancer patients. Prepared June 2010. [BAC and FR, writers]
Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs. 2010;14(1):81-86. [FR, collaborating writer]
Lemmens L. Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe. Poster presented at the 2010 meeting of the European Oncologic Nursing Society. [FR, collaborating writer]
Protection against bone loss in patients with nonmetastatic prostate cancer treated with androgen deprivation therapy. Review article for urology nurses, prepared September 2009. [FR, collaborating writer]
Publication plan for the manufacturer of an erythropoiesis-stimulating agent. Prepared May to December 2009. [BAC, researcher]
Renwick W, Pettengell R, Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs. 2009;23(3):175-186. [FR, collaborating writer]
Quantitative literature analyses about erythropoiesis-stimulating agents. Prepared May 2006 and May 2008. [BAC, researcher]
Kearney N, Friese C. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: implications for oncology nursing. Eur J Oncol Nurs. 2008;12(1):14-25. [FR, collaborating writer]
Mehta VK, Abboud-Finch M, Petersen JA, Marron JT. Impact of mucositis on patient experience during treatment for head and neck cancer. J Clin Oncol. 2008;26(15S):abstract 17034. [FR, collaborating writer]
Rader M. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits. Oncology. 2006;20(5 suppl):16-21. [FR, collaborating writer]

Meeting report, national advisory board on supportive care in cancer. Prepared September 2005. [FR, writer]
Posters for ASH, ASCO, and MASCC/ISOO annual meetings, 2005. Multiple topics regarding supportive care for cancer patients. [FR, collaborating writer]
Posters for ASCO and MASCC/ISOO annual meetings, 2004. Multiple topics regarding supportive care for cancer patients. [FR, collaborating writer]

Supportive care for immune checkpoint inhibitor therapy
Published by Mass General Brigham [FR, writer]:

Concurrent Immunosuppressive Therapy With Restart of Checkpoint Inhibitor Reduces Risk of Recurrent Immune-related Enterocolitis, 10-9-2023.
Lower steroid dose for initial management of hepatitis secondary to immune checkpoint inhibitors, 2-14-2022.
Pembrolizumab and nivolumab not linked to increased mortality in cancer patients with interstitial lung disease, 6-9-2021.
T1 value on cardiac MRI diagnoses myocarditis associated with checkpoint inhibitors, 6-1-2021.
Immune checkpoint inhibitor therapy increases risk of atherosclerotic cardiovascular events, 12-23-2020.
Myocarditis from immune checkpoint inhibitors potentially mitigated by early corticosteroid, 8-27-2020.
Subset of cancer patients with checkpoint inhibitor–associated enterocolitis respond to budesonide, 1-6-2020.
Researchers chart the course of severe checkpoint inhibitor-related colitis, 8-16-2019.
Flu vaccination might protect against myocarditis related to checkpoint inhibitors, 4-1-2019.

Survivorship

Stress Management Intervention Designed for Cancer “Curvivors” Also Benefits “Metavivors.” Published by Mass General Brigham, 11-27-2023. [FR, writer]
Report on preserving fertility for cancer patients. University of Florida newsletter. Prepared February 2020. [BAC, writer]
Caley BA. Taking control: cancer patients deal with fear. CURE: Cancer Updates, Research and Education. 2006;5(3):64-68.
Caley BA. Going against the odds [living with metastatic cancer]. CURE: Cancer Updates, Research and Education. 2005;4(2):56-58,60. Also wrote two of the three sidebars to this article: Disrupting metastasis; The future of metastasis treatment.
Herman R. Cultural diversity and cancer patient education. Poster presented at the 2004 meeting of the Oncology Nursing Society. [FR, collaborating writer]
Reidenbach F. Conceiving solutions: fertility and cancer treatment. CURE: Cancer Updates, Research and Education. 2002;1(4):22-26.
Reidenbach F. Chemotherapy safe in pregnancy. Lancet Oncol. 2002;3:128.
Reidenbach F. Mental difficulties can persist long after chemotherapy. Reuters news for the public, 2-11-2002.

Targeted therapy generally

CME slide set about the differences between small-molecule drugs, biologics, and biosimilars. Prepared October 2010. [BAC and FR, writers]
Quantitative literature review about angiogenesis inhibitors. Prepared May 2006. [BAC, researcher]
Review article about the safety of using anti-angiogenic therapy in elderly patients or patients with poor performance status. Prepared January 2006. [FR, collaborating writer]
Meeting report, national advisory board on angiogenesis inhibitors. Prepared December 2005. [FR, writer]
Educational newsletter for sales representatives about targeted therapy. Prepared Spring 2004. [FR, writer]
Reidenbach F. Angiogenesis inhibitor plus paclitaxel well tolerated in phase 1 trial. Reuters news for physicians, 12-5-2002.
Reidenbach F. Resistance to antiangiogenic agents may reflect variance in tumor biology. Reuters news for physicians, 10-03-2002.
Reidenbach F. First cholinergic pathway for angiogenesis identified. Reuters news for physicians, 9-10-2002.

Testicular cancer

Biomarkers in testicular cancer. Published by Mass General Brigham, 2-17-2023. [FR, writer]
Checkpoint inhibitors and other immunotherapies in urologic cancer. Published by Mass General Brigham, 5-9-2023. [FR, writer]

Thyroid cancer

Vocal cord paralysis commonly asymptomatic in patients with recurrent laryngeal nerve invasion by thyroid cancer. Published by Mass General Brigham, 5-5-2023. [FR, writer]

Selpercatinib shows marked antitumor activity in RET-altered thyroid cancer. Published by Mass General Brigham, 3-16-2021. [FR, writer]
Are thyroid nodules cancerous? Taking Care. October 2005. [BAC, writer]

Vulvar cancer

Lymph node evaluation underutilized for early-stage vulvar cancer. Published by Mass General Brigham, 3-6-2023. [FR, writer]

","verticalAlignment":"top"},"metaData":{"position":{"left":-437,"top":357},"size":{"width":858,"height":9946}}},{"type":"freeText","id":"id1481498290691","elementProperties":{"tagName":"H3","behaviours":null,"isLocked":false,"name":"Text 1","baseName":null,"templateID":"templateid1481498290696","templateName":null,"order":47,"customStates":null,"isElementWasEditedInMode":false,"showHoverEffects":true,"skinInformation":{},"isSupportsMobile":false,"isVisibleInMode":true,"isFixed":false,"topZIndex":0,"elementOpacity":1,"staticMargin":{"horizontalMargin":0,"verticalMargin":0},"sizeAndPosition":{"width":326,"height":34,"left":-451,"top":26},"lastResizingSize":{"width":326,"height":34,"left":-451,"top":26},"isVisibleInLastSection":true,"isVisibleInLastDataItem":true,"attributes":null,"metaProps":null,"metaItemType":null,"metaTitle":null,"styleBindingId":null,"styleBindingFields":null,"shadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"glow":{"spread":0,"blur":0,"color":"black"},"isParallaxBackground":false,"parallaxBackgroundSpeed":0.5,"isParallaxElement":{"isActive":false,"speed":1,"delay":0},"effectsOptions":{"isParallax":false,"oneTimeAnimation":false,"duration":1200,"startDistance":200,"startVisibility":0.8,"distance":300,"measureDistanceType":3,"delay":0,"distanceDelay":0,"runInLoop":false,"flyDirection":2,"direction":"horizontal","movementDistanceHorizontally":200,"movementDistanceVertically":0,"autoStartDistanceSettings":true,"autoDistanceSettings":true},"effects":null,"binding":null,"innerGlow":{"spread":0,"blur":0,"color":"black"},"innerShadow":{"top":0,"left":0,"spread":0,"blur":0,"color":"black"},"display":"fixed","cellItem":null,"cellHorizontalAlignment":"none","basicUserCanEdit":true,"backgroundColor":"transparent","imageUrl":"","imageLayout":"stretchedToFill","imagePosition":{"vertical":"center","horizontal":"center"},"origImage":"","imageOpacity":1,"backgroundOverlay":"transparent","isVisible":true,"verticalLayout":"normal","horizontalLayout":"normal","fillLayout":{"fillHorizontal":false,"fillVertical":false},"margin":{"top":0,"left":0,"bottom":0,"right":0},"borderWidth":{"top":0,"left":0,"bottom":0,"right":0},"roundness":{"topLeft":0,"bottomLeft":0,"topRight":0,"bottomRight":0},"borderColor":{"top":"Black","left":"Black","bottom":"Black","right":"Black"},"borderStyle":{"top":"solid","left":"solid","bottom":"solid","right":"solid"},"padding":{"top":0,"left":0,"bottom":0,"right":0},"rotationAngle":0,"verticalAlign":"center","horizontalAlign":"left","horizontalContentAlign":"center","startSelected":false,"urlAddress":null,"openInNewTab":false,"openInTopWindow":false,"shouldUnderlineChildren":false,"namedTextStyle":null,"fontColor":{"mainColor":2,"opacity":1,"brightness":0},"textShadow":[],"lineHeight":{"percentages":120,"unit":"percentages"},"letterSpacing":0,"fontSize":20,"font":{"themeFont":"body1"},"contentTextTransform":"none","isBold":false,"isItalic":false,"isUnderline":false,"textStyle":{"bold":false,"underline":false,"italic":false},"textDirection":2,"dataBinding":null,"formattedText":"

Oncology

","verticalAlignment":"top"},"metaData":{"position":{"left":-451,"top":277},"size":{"width":326,"height":34}}}]}],"offset":{"left":231,"top":64}}],"connections":{"targetConnections":{},"sourceConnections":{}},"customStatesProperties":{},"pageId":"id1480980038682","version":17.004,"id":"id1717018756056","relativePoint":{"left":231,"top":64}}